Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (NYSE American: AIM) announced the publication of a significant peer-reviewed article in the Journal for ImmunoTherapy of Cancer. The research demonstrates a positive combination effect of AIM's drug Ampligen when used with interferon-alpha on tumor growth and patient survival.
The study reveals that systemic chemokine modulation can overcome PD-1 resistance in cold tumors, highlighting that intratumoral cytotoxic t-lymphocyte accumulation is the crucial factor in immune checkpoint inhibitor effectiveness. The findings suggest promising potential for tumor microenvironment reprogramming strategies in cancer treatment.
AIM ImmunoTech (NYSE American: AIM) presented the latest progress of its lead drug candidate Ampligen for pancreatic cancer treatment at the 5th Annual Marie Skłodowska-Curie Symposium in Poland. The presentation highlighted positive data from both the Phase 2 DURIPANC clinical trial and an Early Access Program, focusing on Progression-Free Survival and Overall Survival metrics.
The company's ongoing Phase 2 DURIPANC study evaluates Ampligen in combination with AstraZeneca's durvalumab for treating late-stage metastatic pancreatic cancer. Notably, Ampligen has secured patent protection through 2039 and holds both US and EU orphan drug designations for market protection upon approval.
AIM ImmunoTech (NYSE American: AIM) has released its latest CEO Corner segment featuring CEO Thomas Equels. The segment, now available on the company's website, provides a comprehensive corporate update and focuses on the development progress of Ampligen, the company's lead product candidate, particularly in pancreatic cancer treatment.
The update includes details about recent scientific advancements and the company's strategic direction in advancing Ampligen's development program.
AIM ImmunoTech (NYSE:AIM) has reported its Q2 2025 financial results and provided updates on its pipeline programs. The company's primary focus remains on its Phase 2 DURIPANC trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for pancreatic cancer treatment, which has shown promising signs regarding toxicity, progression-free survival (PFS), and overall survival (OS).
The company recently raised $8.0 million through a public offering in July 2025, extending its operational runway for approximately 12 months. Financial results show a net loss of $2.8 million ($3.68 per share) for Q2 2025, compared to $1.8 million ($3.00 per share) in Q2 2024. Cash position stood at $835,000 as of June 30, 2025.
AIM ImmunoTech (NYSE American: AIM) announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series focused on Biotech/MedTech companies. The virtual presentation will be delivered by Thomas Equels, the company's CEO, President & Executive Vice Chairman, on Wednesday, August 20, 2025 at 2:40 PM ET. The event is part of a larger virtual conference taking place from August 19-21, 2025.
AIM ImmunoTech (NYSE American: AIM) announced that its drug Ampligen will be featured in four presentations at the 5th Annual Marie Skłodowska-Curie Symposium in Warsaw, Poland from September 3-5, 2025. The presentations will highlight positive clinical data across multiple areas:
The DURIPANC Phase 2 study shows promising results for pancreatic cancer treatment, with 21% of patients achieving PFS >6 months and 64% reaching OS >6 months. Additional presentations will cover Ampligen's effectiveness in other solid tumors, including ovarian, triple-negative breast, and colorectal cancers.
Notably, analysis of previous clinical trials revealed Ampligen's potential in treating endometriosis, showing approximately 80% symptom improvement in female participants, opening new therapeutic possibilities for this condition affecting 190 million women globally.
AIM ImmunoTech (NYSE American: AIM) has provided an update on its clinical development progress, focusing primarily on Ampligen® (rintatolimod) for pancreatic cancer treatment. The company reported positive mid-year data from its Phase 2 DURIPANC study combining Ampligen® with AstraZeneca's Imfinzi® (durvalumab), showing promising progression-free survival (PFS) and overall survival (OS) with no significant toxicity.
Key achievements include raising $8.0 million through a public equity offering, providing approximately 12 months of operational funding. The company has also secured multiple U.S. patents for Ampligen®, received U.S. and EU Orphan Drug designations for pancreatic cancer, and resumed trading on the NYSE American.
AIM ImmunoTech (NYSE American: AIM) has completed its previously announced public offering, raising $8.0 million in gross proceeds. The offering consisted of 2,000,000 shares of common stock (or pre-funded warrants) along with Class E and Class F warrants at a combined price of $4.00 per share.
The offering included Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with an exercise price of $4.00 per share. Maxim Group LLC served as the sole placement agent for this transaction, which was conducted under an effective S-1 registration statement.
AIM ImmunoTech (NYSE American: AIM) has announced the pricing of a $8.0 million public offering. The offering consists of 2,000,000 shares of common stock (or pre-funded warrants), along with Class E and Class F warrants, priced at $4.00 per share.
The offering includes Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with a $4.00 exercise price. Maxim Group LLC is serving as the sole placement agent, with the offering expected to close around July 30, 2025.
AIM ImmunoTech (NYSE American: AIM) has reported positive mid-year data from its Phase 2 DURIPANC study, evaluating the combination of Ampligen® (rintatolimod) with AstraZeneca's Imfinzi® (durvalumab) for treating metastatic pancreatic cancer patients.
The study, conducted in collaboration with AstraZeneca and Erasmus Medical Center, has enrolled 14 out of 25 planned subjects. Key findings include: no significant toxicity, approximately 21% of patients showing PFS >6 months, and 64% of eligible patients achieving OS >6 months. The trial builds on previous successful results of Ampligen as a monotherapy in over 50 pancreatic cancer patients.
AIM has secured intellectual property protection through a U.S. patent extending to 2039 and orphan drug designations in both the U.S. and EU for Ampligen in pancreatic cancer treatment.